Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ bone marrow endothelial progenitor cells
- Development stage
- Unknown
- Lead developer
- Andalusian Progress and Health Public Foundation
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
Autologous CD133+ bone marrow endothelial progenitor cells (BM-EPCs) is a personalized cell-based biologic therapy. It involves harvesting the patient's own bone marrow, isolating CD34+/CD133+ progenitor cells, and re-administering them via intra-arterial infusion. These cells possess vasculogenic and regenerative properties, intended to induce therapeutic angiogenesis and vasculogenesis in ischemic tissues. The therapy is primarily investigated for treating chronic critical lower-limb ischemia (CLI) in patients with type 2 diabetes mellitus, aiming to improve limb perfusion, promote ulcer healing, and reduce amputation rates.
- Other names
- autologous CD133+ bone marrow endothelial progenitor cellsautologous CD133+ BM-EPCsautologous CD34+/CD133+ bone marrow-derived endothelial progenitor cellsautologous CD133+ bone marrow-derived endothelial progenitor cells
Beyond the preview
Go deeper on autologous CD133+ bone marrow endothelial progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ bone marrow endothelial progenitor cells.